DDInter513 DDInter1747
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Dexamethasone {u} (Compound) resembles {v} (Compound) Fludrocortisone
Dexamethasone {u} (Compound) resembles {v} (Compound) Triamcinolone
Dexamethasone {u} (Compound) treats {v} (Disease) psoriatic arthritis
Dexamethasone {u} (Compound) binds {v} (Gene) CYP3A7-CYP3A51P
Dexamethasone {u} (Compound) upregulates {v} (Gene) PCYOX1L
Dexamethasone {u} (Compound) palliates {v} (Disease) kidney cancer
Dexamethasone {u} (Compound) is included by {v} (Pharmacologic Class) Corticosteroid Hormone Receptor Agonists
Dexamethasone {u} (Compound) downregulates {v} (Gene) DNAJB6
Dexamethasone {u} (Compound) causes {v} (Side Effect) Vitreous opacities
Dexamethasone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium bicarbonate
Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Dexamethasone (Compound) resembles Triamcinolone (Compound)
Dexamethasone (Compound) treats psoriatic arthritis (Disease)
Dexamethasone (Compound) binds CYP3A7-CYP3A51P (Gene)
Dexamethasone (Compound) upregulates PCYOX1L (Gene)
Dexamethasone (Compound) palliates kidney cancer (Disease)
Dexamethasone (Compound) is included by Corticosteroid Hormone Receptor Agonists (Pharmacologic Class)
Dexamethasone (Compound) downregulates DNAJB6 (Gene)
Dexamethasone (Compound) causes Vitreous opacities (Side Effect)
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate